1. Home
  2. NTRA vs KEY Comparison

NTRA vs KEY Comparison

Compare NTRA & KEY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • KEY
  • Stock Information
  • Founded
  • NTRA 2003
  • KEY 1825
  • Country
  • NTRA United States
  • KEY United States
  • Employees
  • NTRA N/A
  • KEY N/A
  • Industry
  • NTRA Medical Specialities
  • KEY Major Banks
  • Sector
  • NTRA Health Care
  • KEY Finance
  • Exchange
  • NTRA Nasdaq
  • KEY Nasdaq
  • Market Cap
  • NTRA 27.0B
  • KEY 20.8B
  • IPO Year
  • NTRA 2015
  • KEY N/A
  • Fundamental
  • Price
  • NTRA $205.15
  • KEY $17.54
  • Analyst Decision
  • NTRA Strong Buy
  • KEY Buy
  • Analyst Count
  • NTRA 16
  • KEY 16
  • Target Price
  • NTRA $220.38
  • KEY $20.41
  • AVG Volume (30 Days)
  • NTRA 1.4M
  • KEY 17.9M
  • Earning Date
  • NTRA 11-06-2025
  • KEY 10-16-2025
  • Dividend Yield
  • NTRA N/A
  • KEY 4.65%
  • EPS Growth
  • NTRA N/A
  • KEY 34785.88
  • EPS
  • NTRA N/A
  • KEY 0.86
  • Revenue
  • NTRA $2,116,676,000.00
  • KEY $5,934,000,000.00
  • Revenue This Year
  • NTRA $25.70
  • KEY $77.14
  • Revenue Next Year
  • NTRA $15.42
  • KEY $6.45
  • P/E Ratio
  • NTRA N/A
  • KEY $20.37
  • Revenue Growth
  • NTRA 38.17
  • KEY 22.30
  • 52 Week Low
  • NTRA $125.38
  • KEY $12.73
  • 52 Week High
  • NTRA $212.21
  • KEY $20.04
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 65.15
  • KEY 46.20
  • Support Level
  • NTRA $182.20
  • KEY $17.17
  • Resistance Level
  • NTRA $212.21
  • KEY $18.47
  • Average True Range (ATR)
  • NTRA 8.09
  • KEY 0.38
  • MACD
  • NTRA 0.00
  • KEY 0.05
  • Stochastic Oscillator
  • NTRA 75.84
  • KEY 34.65

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About KEY KeyCorp

With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.

Share on Social Networks: